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Abstract There are some data showing lower mortality
of smokers comparing to non-smokers in patients with ST-
segment elevation myocardial infarction (STEMI) when
treated with thrombolysis or without reperfusion therapy.
However, the role of smoking status is less established in
patients with STEMI undergoing mechanical reperfusion.
We evaluate the influence of smoking on outcome in
patients with STEMI treated with primary percutaneous
coronary intervention (PCI). A total of 1,086 patients
enrolled into EUROTRANSFER Registry were included
into present analysis. Patients were divided according to
smoking status during STEMI presentation into those who
were current smokers (391 patients, 36 %) and non-
smokers (695 patients, 64 %). Current smokers were
younger and more often men and less frequently had high-
risk features as previous myocardial infarction, history of
chronic renal failure, previous PCI, diabetes mellitus,
anterior wall STEMI, and multivessel disease. Unadjusted
mortality at 1 year was lower in current smokers compar-
ing to non-smokers (3.3 vs. 9.5 %; OR 0.33 CI 0.18–0.6;
p = 0.0001). However, after adjustment for age and gender
by logistic regression, there was no longer significant dif-
ference between groups (OR 0.7; CI 0.37–1.36; p = 0.30).
In conclusion, current smokers with STEMI treated with
primary PCI have lower mortality at 1 year comparing to
non-smokers, but this result may be explained by differ-
ences in baseline characteristics and not by smoking status
itself. Current smokers developed STEMI more than
10 years earlier than non-smokers with similar age and
sex-adjusted risk of death at 1 year. These results empha-
size the role of efforts to encourage smoking cessation as
prevention of myocardial infarction.
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Introduction
Smoking is a well-known risk factor for coronary artery
disease, and is associated with increased rates of myocar-
dial infarction and cardiovascular death [1–3]. However,
there are some data showing lower mortality of smokers
comparing to non-smokers in patients with ST-segment
elevation myocardial infarction (STEMI), especially when
treated with thrombolysis or without reperfusion therapy
[4–6]. This effect was confirmed even after adjustment for
confounding factors by multivariate analysis. Thus, based
on such residual survival benefit for smokers, the phe-
nomenon called ‘‘smoker’s paradox’’ was described.
The impact of smoking on outcome in patients with
STEMI treated with primary percutaneous coronary inter-
vention (PCI) is less established. The aim of present study
was to examine the influence of smoking on outcome in
patients with STEMI treated with primary PCI based on
data from large scale, multicenter European Registry on
Patients with ST-Elevation MI Transferred for Mechanical
Reperfusion with a Special Focus on Upstream Use of
Abciximab (EUROTRANSFER) Registry.
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Methods
Study population
EUROTRANSFER Registry was an international, pro-
spective, multicenter European registry. Patient data were
collected in 15 STEMI hospital networks from 7 European
countries between November 2005 and January 2007
(www.eurotransfer.org). The registry collected data on
1,650 consecutive STEMI patients C18 years old who were
scheduled for primary PCI and who arrived to the PCI-
hospital by transfer from either a referral hospital or were
picked-up from an ambulance, which could provide quali-
fied medical therapy. Patients who arrived to the PCI-hos-
pital from other pathways than those specified above, e.g.,
those who came by ambulances that did not provide specific
medical therapy or presented directly to the emergency
room of the PCI-hospital were excluded from the registry.
EUROTRANSFER Registry was registered at Clinical-
Trials.gov (NCT00378391). The study protocol and exe-
cution complied with the Declaration of Helsinki and has
been approved by the Jagiellonian University Bioethics
Committee in Krakow, Poland.
Detailed registry description, definitions, and main results
have been reported previously [7–9]. For the purpose of this
analysis 1,086 patients who received abciximab were
retrieved from the total registry population. Patients were
divided according to smoking status during STEMI presen-
tation into those who were current smokers (current smokers
or former smokers who stopped smoking less than 30 days
prior to the event) and non-smokers (never smoking patients
or former smokers who stopped smoking more than 30 days
prior to the event). Patients were also stratified according to
the risk profile criteria proposed by Thrombolysis In Myo-
cardial Infarction (TIMI) investigators [10]. Patients with 0–2
points in TIMI risk score on admission were considered as
‘‘low-risk,’’ whereas patients with equal or more of 3 point
were considered to be ‘‘high-risk’’ patients. We analyzed the
influence of smoking on 30 day and 1 year clinical outcomes.
Study outcomes
Clinical outcome was evaluated through monitoring of
major adverse cardiovascular events (all-cause death,
reinfarction) and bleeding complications: intracranial
hemorrhage, major bleeding requiring transfusion, at
30 days after PCI. Patients were followed-up for all-cause
death until 1 year, which was the primary outcome
parameter. TIMI flow in infarct-related artery before and
after PCI, ST-segment resolution [50 % in electrocardio-
gram 60 min after PCI were assessed at investigators’
discretion. Also, information on the rates of PCI compli-
cations (no-reflow, distal embolization) were collected.
Statistical analysis
Data were analyzed according to the established standards
of descriptive statistics. Results were presented as numbers
(percentages) of patients or medians (inter-quartile range)
where applicable. Differences between groups stratified by
smoking status were tested by v2 test and the Fisher’s exact
test for dichotomous variables and the Mann–Whitney
U test for continuous variables. Then, differences in clin-
ical outcome between smokers and non-smokers were
assessed. Results were adjusted for age and gender by
logistic regression analysis. In addition, data on 30 day and
1 year mortality for smokers and non-smokers were pre-
sented for four pre-specified age groups (\55, 55–64,
65–74, C75 years of age).
The difference in death rates between groups during
follow-up period was assessed by the Kaplan–Meier
method by means of the log-rank test. All tests were
2-tailed and a p value of\0.05 was considered statistically
significant. All statistical analysis was performed by means
of SPSS 15.0 (SPSS Inc., Chicago, Illinois).
Results
A total of 1,086 patients with STEMI who received ab-
ciximab entered current analysis of EUROTRANSFER
Registry. Patients were divided according to smoking sta-
tus for current smokers (391 patients, 36 %) and for non-
smokers (695 patients, 64 %). Baseline characteristics are
presented in Table 1 and Fig. 1. Current smokers were
younger and more often men. In the non-smokers group,
the rate of high-risk features as previous myocardial
infarction, history of chronic renal failure, previous PCI,
diabetes mellitus, anterior wall STEMI, and multivessel
disease was more frequent than in the current smokers
group. Area under the curve (c statistic) of TIMI risk score
showed high predictive accuracy for 1 year mortality in the
study population (0.785; 95 % CI 0.729–0.841; p \ 0.001).
Smokers were more often classified as ‘‘low-risk’’
according to TIMI risk score comparing to non-smokers.
When patients’ distribution was analyzed according to age,
imbalanced proportion was found with larger proportion of
younger patients in smokers’ cohort and older patients in
non-smokers. There were no differences between smokers
and non-smokers in TIMI risk score profile in predefined
age groups (Fig. 1). Concomitant medication and proce-
dure details are presented in Table 2. Angiography
revealed similar rate of patient (TIMI flow grade 2 or 3)
infarct-related artery before PCI in both groups. Immediate
PCI was performed in about 95 % of patients from both
groups. Final angiographic PCI result (TIMI flow grade 3
rate) was better in the current smokers group. ST-segment
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resolution C50 % in electrocardiogram assessed 60 min
after PCI was more frequent in the current smokers group.
Impact of smoking on clinical outcome
Clinical follow-up is summarized in Table 3. During
30 day follow-up, the rate of death and or reinfarction was
lower in the current smokers group. There was no signifi-
cant difference in bleeding complications rate between
study groups. During 1 year follow-up, lower mortality
was observed in current smokers comparing to the non-
smokers group. Kaplan–Meier curves for 1 year survival
showed lower mortality in current smokers comparing to
non-smokers (Fig. 2). However, after adjustment for age
and gender by logistic regression analysis, there was no
longer significant difference in clinical outcome between
current smokers and non-smokers. Adjustment for addi-
tional covariates had little effect. Similarly, there were no
significant differences for both 30 day and 1 year death for
smokers and non-smokers when analyzed in predefined age
groups (Fig. 3).
Discussion
In the current analysis of EUROTRANSFER Registry on
STEMI patients treated with primary PCI under real life
conditions in high-volume primary-PCI centers, current
smokers had lower mortality at 1 year comparing to
non-smokers, but this difference was no longer significant
after adjustment for age and gender. Interestingly current
smokers developed STEMI more than decade earlier than
non-smokers. These results emphasize the role of efforts to
encourage smoking cessation as primary and secondary
prevention in myocardial infarction.
Residual survival benefit for smokers called ‘‘smoker’s
paradox’’ was described more than 25 years ago. It was
supported by some of the large scale randomized trials with
Table 1 Baseline
demographics and clinical status
on admission to PCI centre.
Timing information
BP blood pressure, CABG
coronary artery bypass grafting,
IQR inter-quartile range, PCI
percutaneous coronary
intervention, SD standard
deviation
Current smokers
(n = 391)
Non-smokers
(n = 695)
p
Age, years (IQR) 56 (48–65) 68 (60–76) \0.0001
Males 81.6 % 71.2 % 0.00015
Body-mass index, kg/m2 median (IQR) 26.2 (23.9–29.3) 27.1 (24.4–29.6) 0.01
Systolic BP, mmHg, median (IQR) 130 (113–150) 130 (117–150) 0.4
Diastolic BP, mmHg, median (IQR) 80 (70–90) 80 (70–90) 0.36
Heart rate, beats per 1 min, median (IQR) 75 (67–85) 77 (66–90) 0.2
Previous myocardial infarction 6.9 % 13.7 % 0.0007
History of chronic renal failure 0.8 % 3.2 % 0.01
Previous stroke 2.1 % 4.2 % 0.06
Previous PCI 4.9 % 10.2 % 0.002
Previous CABG 0.5 % 1.9 % 0.1
Peripheral artery disease 3.3 % 2.3 % 0.31
Diabetes mellitus 10 % 18.6 % 0.0002
Killip IV on cathlab admission 2.1 % 3.6 % 0.15
Pain-to-abciximab time, minutes, median (IQR) 150 (90–240) 153 (90–265) 0.24
Abciximab-to-balloon time, minutes, median (IQR) 57 (1–80) 63 (1–88) 0.13
Pain-to-balloon time, minutes, median (IQR) 202 (148–296) 216 (148–340) 0.06
TIMI risk score, median (IQR) 2 (1–3) 3 (2–5) \0.0001
TIMI risk score ‘‘low-risk’’ 62.2 % 32.7 % \0.0001
Fig. 1 Distribution of patients according to age and smoking status.
TIMI Risk Score (TIMI RS) presented as median and inter-quartile
range. Insignificant differences in TIMI RS between current smokers
and non-smokers (p [ 0.2)
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thrombolysis. Both Global Utilization of Streptokinase and
Tissue-Plasminogen Activator for Occluded Coronary
Arteries (GUSTO-I) trial and the International Tissue-
Plasminogen Activator/Streptokinase Mortality Trial dem-
onstrated lower adjusted mortality rate in smokers
compared to non-smokers [4, 5]. Similar observation sup-
porting ‘‘smoker’s paradox’’ was found in the large scale
National Registry of Myocardial Infarction 2 (NRMI 2)
registry analysis on myocardial infarction patients but rate
of reperfusion (PCI, CABG, and thrombolysis) was below
30 % in those patients [6]. In contrary, in the analysis of
The Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarcto Micardico (GISSI-2) trial, beneficial effect of
smoking was not confirmed since the study showed similar
adjusted in-hospital mortality for smokers comparing to
non-smokers [11]. Several potential explanations of
‘‘smoker’s paradox’’ were proposed. It was suggested that
current smokers with myocardial infarction more often
Table 2 Concomitant
medications. Angiographic and
interventional details
IABP intraaortic balloon
pumping, IRA infarct-related
artery, LAD left anterior
descending artery, LCX left
circumflex artery, LMCA left
main coronary artery, PCI
percutaneous coronary
intervention, RCA right
coronary artery, STR ST-
segment resolution, SVG
saphenous vein graft, TIMI
thrombolysis in myocardial
infarction
Current smokers
(n = 391) (%)
Non-smokers
(n = 695) (%)
p
Clopidogrel loading dose pre-cathlab 23.5 22.8 0.8
Unfractionated heparin pre-cathlab 70.1 71.1 0.73
Abciximab pre-cathlab 65.4 67.8 0.44
IRA in baseline angiography
SVG 0.3 0.7
LMCA 0.5 1
LAD 43.2 49.8
LCX 15 10
RCA 41 38.5 0.047
Multi-vessel disease 45.1 54.9 0.001
Immediate PCI 94.9 94.4 0.72
Thrombectomy usage 10.7 12.2 0.46
Stent (total) 91 86.2 0.02
Drug-eluting stent 31.7 27.5 0.14
Direct stenting 19.4 13.8 0.014
IABP 2.3 4.9 0.04
No-reflow during PCI 2.6 3.9 0.25
Distal embolization during PCI 1.3 2.5 0.15
TIMI grade 2–3 flow before PCI 28.9 27.5 0.62
TIMI grade 3 flow after PCI 94.1 89.6 0.016
STR [ 50 % after PCI 80.6 71.8 0.001
Table 3 Clinical outcome at 30 day and 1 year follow-up
Current smokers
(n = 391)
Non-smokers
(n = 695)
OR, (95 % CI) p Adjusteda OR,
(95 % CI)
p
Ischemic complications at 30 day
Death 2.3 % (9) 6.6 % (46) 0.33 (0.16–0.69) 0.002 0.71 (0.32–1.54) 0.38
Death ? reinfarction 3.3 % (13) 8.1 % (56) 0.39 (0.21–0.73) 0.002 0.81 (0.42–1.59) 0.54
Bleeding complications at 30 day
Stroke, hemorrhagic 0 0
Major bleedings requiring transfusion 1.8 % (7) 2.2 % (15) 0.82 (0.33–2.04) 0.68 1.33 (0.48–3.70) 0.58
All bleedings 7.4 % (29) 10.8 % (75) 0.66 (0.42–1.04) 0.07 0.83 (0.51–1.36) 0.46
Ischemic complications at 1 year
Death 3.3 % (13) 9.5 % (66) 0.33 (0.18–0.6) 0.0001 0.71 (0.37–1.36) 0.30
CI confidence interval, OR odds ratio
a Adjusted for age and gender
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suffer sudden cardiac death before hospital admission so
patients enrolled in clinical studies represent lower-risk
survivors [12]. Many studies describe some differences in
pathogenesis of myocardial infarction in smokers sug-
gesting that smokers may respond better to either sponta-
neous or therapeutic thrombolysis. In the Second
Multicenter Thrombolytic Trials of Eminase in Acute
Myocardial Infarction (TEAM-2) study, current smokers
were more likely to achieve TIMI grade 3 flow after lytics
administration than non-smoking patients [13]. Better
response to thrombolysis may be also related to larger
thrombus burden than plaque burden proportion in the
infarct-related artery. Some angiographic morphological
features indicating high burden thrombus formation were
previously described including vessel size, minimal lumen
diameter, infarct-related artery cutoff pattern of occlusion,
accumulated thrombus proximal to the occlusion, and
culprit location [14–16]. Lower number of angiographic
re-occlusions (and clinical reinfarctions) in smokers may
be also in favor of dominant thrombogenic etiology of
artery occlusion in those patients [17]. In addition, in the
TIMI phase II trial (TIMI II) and in GUSTO-I angiographic
substudy current smokers had less multivessel disease than
other patients what also may influence outcome [5, 17].
Primary PCI is more effective than thrombolysis in the
restoration of the flow in the infarct-related artery. More-
over, mechanical plaque stabilization results in lower rate
of artery re-occlusion. Therefore, influence of above-
mentioned factors on treatment effects in smokers may be
weaker than showed in thrombolytic studies. In the analysis
of the Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications (CADILLAC) trial
on 2,082 patients treated with primary PCI for STEMI,
lower 30 day and 1 year mortality was found for current
smokers compared to former smokers and non-smokers.
However, after multivariable corrections for baseline
characteristics, there was no longer beneficial effect of
smoking on mortality. In addition, current smokers were
about 10 years younger than non-smokers and had lower
rate of risk factors including diabetes, hypertension, pre-
vious acute myocardial infarction, and multivessel disease
which is similar to our observations [18]. Similarly, in
HORIZONS-AMI analysis smokers, compared to non-
smokers had significantly lower rates of mortality and
major bleeding at 30 days and at 1 year. However, the
differences were no longer significant after covariate
adjustment [19]. Beyond CADILLAC and HORIZONS-
AMI analysis, the data concerning influence of smoking on
mortality in patients treated with primary PCI are very
limited. Thus, we performed analysis of patients treated
with primary PCI with up to date pattern. Smoking analysis
was also performed based on The Global Registry of Acute
Coronary Events (GRACE) including patients with
STEMI, NSTEMI, and unstable angina. The proportion of
current smokers was the highest in STEMI patients, which
is consistent with previous reports. In STEMI cohort, PCI
was performed in about 40 % of patients. Importantly,
current smokers were more often treated with PCI and
more likely to receive evidence-based medicine therapy
then others. Current smokers had the lowest unadjusted
mortality; but, after adjustment, there was no difference in
the rate of in-hospital death among studied groups [20].
These results are along to our observations, but we were
Fig. 2 Kaplan–Meier survival curves for 1 year follow-up
Fig. 3 Mortality at 30 day (a) and 1 year (b) in predefined age
groups
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able to analyze not only short term but also 1 year
mortality.
Previous reports and our analysis suggest that ‘‘smoker’s
paradox’’ described in prethrombolytics and thrombolytics
studies does not extend into the primary-PCI era. The
mortality difference may be explained by confounding
factors related to the lower risk profile of current smokers
especially to the younger age. The ‘‘smoker’s paradox’’
term should no longer be used because it may be misun-
derstood by patients and negatively influence smoking
cessation both as primary and secondary prevention. This is
very important since smoking is one of the strongest risk
factors of coronary artery disease, myocardial infarction,
and cardiovascular death. Both American College of Car-
diology/American Heart Association and European Society
of Cardiology STEMI Guidelines strongly encourage
patients and their families to stop smoking and to avoid
secondhand smoke. Smoking cessation is also one of the
most effective measures of secondary prevention after
STEMI; when successful, allows to reduce rate of death in
succeeding years by one third compared to patients who
continue to smoke [21, 22].
Limitations of the study
Presented study has several limitations. The main limita-
tion of the study is its non-randomized nature and the
potential of selection bias. This may especially influence
early vs late abciximab administration analysis because
even with the use of propensity score adjustment, we were
unable to control all factors influencing the association
between early abciximab use and patients’ outcomes. The
smoking status was assessed only at the moment of hospital
admission and not in the follow-up. Also, precise data on
smoking history was not available; so, we have decided to
analyze current smokers vs non-smokers without former
smokers as additional subgroup. The analysis of the TIMI
flow, as well as post-PCI ST-segment resolution, was
performed by physicians and did not represent independent
core laboratory quality. However, it is unlikely that these
limitations could influence the study outcome because both
groups were exposed to these limitations and were rela-
tively large.
Conclusions
Current smokers with STEMI treated with primary PCI have
lower mortality at 1 year comparing to non-smokers, but this
result may be explained by differences in baseline charac-
teristics and not by smoking status itself. Current smokers
developed STEMI 10 years earlier than non-smokers with
similar age and sex-adjusted risk of death at 1 year. These
results emphasize the role of efforts to encourage smoking
cessation as prevention of myocardial infarction.
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